IP Library Granted Patent US 10,092,390
Granted Patent B2
US 10,092,390 · App. 13/168,865 · Granted Oct 9, 2018

Method of making implantable medical devices having controlled surface properties

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,092,390
App. No.
13/168,865
Granted
Oct 9, 2018
Kind
B2
Abstract

An implantable medical device that is fabricated from materials that present a blood or body fluid or tissue contact surface that has controlled heterogeneities in material constitution. An endoluminal stent-graft and web-stent that is made of a monolithic material formed into differentiated regions defining structural members and web regions extending across interstitial spaces between the structural members. The endoluminal stent-graft is characterized by having controlled heterogeneities at the blood flow surface of the stent.

Claims (29)

1. A method for controlling surface properties of an implantable medical device, comprising:

vacuum depositing a device forming biomaterial selected from one of elemental nickel and elemental titanium or nickel-titanium alloy onto a cylindrical substrate maintained at a temperature range between about 300 to 1100 degrees Centigrade, the substrate having a pre-determined pattern of recesses in an outer surface thereof to form a tubular device forming biomaterial on the cylindrical substrate;

controlling the formation of heterogeneities at a blood or tissue contacting surface of the tubular device forming biomaterial during the vacuum depositing step, such that controlled heterogeneities are formed at the blood or tissue contacting surface; and

removing the medical device from the substrate.

2. The method according to claim 1 , further comprising forming cell-adhesion domains having inter-domain boundaries less than the surface area of a human endothelial cell and wherein the substrate has a coefficient of thermal expansion different than that of the resultant implantable medical device.

3. The method according to claim 1 , wherein the controlled heterogeneities are selected from the group consisting of grain size, grain phase and grain composition and luminal surface topography.

4. The method according to claim 1 , wherein the controlled heterogeneities have a blood contact surface of diameter less than or equal to about 10 μm and an inter-heterogeneity boundary between about 0 and 2 μm.

5. A method for controlling surface properties of an implantable medical device, comprising:

forming a tubular nickel-titanium alloy biomaterial onto a substrate maintained at a temperature range between about 300 to 1100 degrees Centigrade and non-zero bias voltage present between about −1000 and +1000 volts applied to the generally cylindrical substrate sufficient to impart a hyperthermal energy of energetic species arriving at the surface of the substrate to between about 0.1 eV and about 700 eV, the substrate having a pre-determined pattern of topographical features on an exterior surface thereof, wherein the pattern of topographical features comprises a positive or negative pattern that is imparted to the device forming biomaterial;

controlling the formation of heterogeneities at a blood or tissue contacting surface of the biomaterial by fabricating the bulk material of the medical device to have a defined grain sizes that yield sites along the surface of the medical device having protein binding capability, wherein the controlled heterogeneities have a blood contact surface of diameter less than or equal to about 10 μm and an inter-heterogeneity boundary between about 0 and 2 μm; and

removing the medical device from the substrate.

6. The method according to claim 5 , wherein the step of controlling the formation of heterogeneities further comprises etching.

7. The method according to claim 5 , further comprising forming cell-adhesion domains having inter-domain boundaries less than the surface area of a human endothelial cell and wherein the substrate has a coefficient of thermal expansion different than that of the resultant medical device.

8. The method according to claim 5 , wherein the controlled heterogeneities are dimensioned to have a blood contact surface area of about less than 6 μm2.

9. The method according to claim 5 , wherein the controlled heterogeneities further include a grain phase and a grain composition.

10. The method according to claim 5 , wherein the controlled heterogeneities are material compositions.

11. The method according to claim 5 , wherein the implantable medical device is a tubular device and the controlled heterogeneities are on the luminal surface topography.

12. A method for controlling surface properties of an implantable medical device, comprising:

vacuum depositing a generally tubular nickel-titanium alloy device onto a substrate, the substrate having a pre-determined pattern of recesses and the substrate is maintained at a non-zero bias voltage present between about −1000 and +1000 volts applied to the generally cylindrical substrate sufficient to impart a hyperthermal energy of energetic species arriving at the surface of the substrate to between about 0.1 eV and about 700 eV;

controlling the formation of heterogeneities at a blood or tissue contacting surface of the biomaterial during fabrication of the medical device, such that controlled heterogeneities are formed and have a substantially homogeneous surface energy and electrostatic charge across a blood contact surface of the metal film, wherein the controlled heterogeneities have a blood contact surface of diameter less than or equal to about 10 μm and an inter-heterogeneity boundary between about 0 and 2 μm; and

removing the medical device from the substrate.

13. The method according to claim 12 , wherein the controlled heterogeneities are selected from the group consisting of grain size, grain phase and grain composition and luminal surface topography.

14. The method according to claim 12 , wherein the step of controlling the formation of heterogeneities further comprises etching.

15. The method according to claim 12 , wherein the controlled heterogeneities are material compositions.

16. The method according to claim 12 , wherein the substrate has a coefficient of thermal expansion different than that of the resultant medical device.

17. The method according to claim 12 , wherein the substrate is maintained at a temperature range between about 300 to 1100 degrees Centigrade.

18. The method according to claim 5 , wherein the controlled heterogeneities are on the luminal surface.

19. The method according to claim 1 , wherein the controlled heterogeneities are dimensioned to have a blood contact surface area of about less than 6 μm 2 .

20. The method according to claim 1 , wherein the substrate is maintained at a non-zero bias voltage present between about −1000 and +1000 volts applied to the generally cylindrical substrate sufficient to impart a hyperthermal energy of energetic species arriving at the surface of the substrate to between about 0.1 eV and about 700 eV.

Assignments (10)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2018
From: VACTRONIX SCIENTIFIC, INC.
To: VACTRONIX SCIENTIFIC, LLC
Reel/Frame 046203/0682 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2018
From: ADVANCED BIO PROSTHETIC SURFACES, LTD., A WHOLLY OWNED SUBSIDIARY OF PALMAZ SCIENTIFIC, INC.
To: VACTRONIX SCIENTIFIC, INC.
Reel/Frame 045709/0763 →
SECURITY INTEREST Recorded Feb 17, 2016
From: PALMAZ SCIENTIFIC INC.; ADVANCED BIO PROSTHETIC SURFACES, LTD.; ABPS VENTURE ONE, LTD.
To: OAK COURT PARTNERS, LTD.
Reel/Frame 037839/0278 →
SECURITY INTEREST Recorded Feb 16, 2016
From: PALMAZ SCIENTIFIC INC.; ADVANCED BIO PROSTHETIC SURFACES, LTD.; ABPS VENTURE ONE, LTD.
To: OAK COURT PARTNERS, LTD.
Reel/Frame 037836/0646 →
SECURITY INTEREST Recorded Feb 16, 2016
From: PALMAZ SCIENTIFIC INC.; ADVANCED BIO PROSTHETIC SURFACES, LTD.; ABPS VENTURE ONE, LTD.
To: OAK COURT PARTNERS, LTD.
Reel/Frame 037827/0568 →
SECURITY INTEREST Recorded Feb 15, 2016
From: PALMAZ SCIENTIFIC INC.; ADVANCED BIO PROSTHETIC SURFACES, LTD.; ABPS VENTURE ONE, LTD.
To: PALMAZ, JULIO
Reel/Frame 037820/0400 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF ASSIGNEE PREVIOUSLY RECORDED AT REEL: 036384 FRAME: 0818. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Aug 24, 2015
From: PALMAZ SCIENTIFIC INC.; ADVANCED BIO PROSTHETIC SURFACES, LTD.; ABPS VENTURE ONE, LTD.
To: LENNOX CAPITAL PARTNERS, LP
Reel/Frame 036465/0091 →
SECURITY INTEREST Recorded Aug 24, 2015
From: PALMAZ SCIENTIFIC INC.; ADVANCED BIO PROSTHETIC SURFACES, LTD.; ABPS VENTURE ONE, LTD.
To: SPI DALLAS INVESTMENTS, LP
Reel/Frame 036434/0813 →
SECURITY INTEREST Recorded Aug 18, 2015
From: PALMAZ SCIENTIFIC INC.; ADVANCED BIO PROSTHETIC SURFACES, LTD.; ABPS VENTURE ONE, LTD.
To: SPI DALLAS INVESTMENTS, LP
Reel/Frame 036384/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2012
From: PALMAZ, JULIO C.; SPRAGUE, EUGENE A.; BANAS, CHRISTOPHER E.
To: ADVANCED BIO PROSTHETIC SURFACES, LTD.
Reel/Frame 027696/0221 →